Pharmaceutical companies Moderna Inc. and Merck & Co. reported that they are working on a vaccine that, together with the anticancer drug Keytruda, reduces the risk of death and recurrence from melanoma. According to the data provided, approximately 80% of vaccinated patients were in remission for 18 months. Bloomberg.
The publication says the study was done in the treatment of people whose melanomas were surgically removed.
About 79% of those who received both Keytruda and the vaccine were in remission for 18 months of the study, and 62% were positive when treated with Keytruda alone.
The papal effects, such as fatigue, were minor, the researchers noted.
Former scientists from the University of Cincinnati to solvethat intestinal microbes can affect survival in pancreatic cancer.